(Q36334866)

13 August 2017

1 reference

title

Exisulind in the treatment of prostate cancer (English)

1 reference

13 August 2017

W Scott Webster

1

1 reference

13 August 2017

Bradley C Leibovich

series ordinal

2

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

957-962

1 reference

13 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Human prostate cancer risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Prostate cancer management: (1) an update on localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Osteoporosis and obesity in men receiving hormone therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Update in the management of patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Exisulind, a selective apoptotic antineoplastic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.957

21 January 2018

Identifiers

DOI

10.1586/14737140.5.6.957

1 reference

13 August 2017

1 reference